- Home
- COLL vs UTL Comparison
COLL vs UTL Comparison
Compare COLL & UTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- COLL
- UTL
- Stock Information
- Founded
- COLL 2002
- UTL 1984
- Country
- COLL United States
- UTL United States
- Employees
- COLL N/A
- UTL N/A
- Industry
- COLL Biotechnology: Pharmaceutical Preparations
- UTL Power Generation
- Sector
- COLL Health Care
- UTL Utilities
- Exchange
- COLL Nasdaq
- UTL Nasdaq
- Market Cap
- COLL 1.1B
- UTL 878.0M
- IPO Year
- COLL 2015
- UTL N/A
- Fundamental
- Price
- COLL $33.35
- UTL $54.80
- Analyst Decision
- COLL Strong Buy
- UTL
- Analyst Count
- COLL 5
- UTL 0
- Target Price
- COLL $43.80
- UTL N/A
- AVG Volume (30 Days)
- COLL 486.5K
- UTL 64.8K
- Earning Date
- COLL 02-20-2025
- UTL 02-11-2025
- Dividend Yield
- COLL N/A
- UTL 3.10%
- EPS Growth
- COLL 757.11
- UTL 5.48
- EPS
- COLL 2.16
- UTL 2.92
- Revenue
- COLL $599,245,000.00
- UTL $496,900,000.00
- Revenue This Year
- COLL $13.20
- UTL $0.73
- Revenue Next Year
- COLL $17.63
- UTL $4.59
- P/E Ratio
- COLL $15.42
- UTL $18.81
- Revenue Growth
- COLL 9.62
- UTL N/A
- 52 Week Low
- COLL $28.39
- UTL $45.26
- 52 Week High
- COLL $42.29
- UTL $63.52
- Technical
- Relative Strength Index (RSI)
- COLL 62.31
- UTL 51.24
- Support Level
- COLL $32.29
- UTL $51.30
- Resistance Level
- COLL $33.99
- UTL $52.76
- Average True Range (ATR)
- COLL 1.29
- UTL 1.18
- MACD
- COLL 0.51
- UTL 0.34
- Stochastic Oscillator
- COLL 87.40
- UTL 81.78
About COLL Collegium Pharmaceutical Inc.
Collegium Pharmaceutical Inc is a specialty pharmaceutical company. The company is engaged in developing and planning to commercialize abuse-deterrent products that incorporate its patented DETERx platform technology for the treatment of chronic pain and other diseases. The DETERx platform technology is designed to maintain the extended-release and safety profiles of highly abused drugs in the face of various methods including chewing, crushing, and dissolving. Its product portfolio includes Xtampza ER, which is an abuse-deterrent, extended-release, oral formulation of oxycodone; and Nucynta Products, which are extended-release and immediate-release formulations of tapentadol; Belbuca, and Symproic.
About UTL UNITIL Corporation
Unitil Corp is a holding company, through its subsidiaries it is engaged in the local distribution of electricity and natural gas throughout its service territories in the states of New Hampshire, Massachusetts, and Maine. It reports three segments namely utility gas operations, utility electric operations, and non-regulated.